Literature DB >> 2321135

Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings.

K Haukipuro1, L Risteli, M I Kairaluoma, J Risteli.   

Abstract

The concentration of the aminoterminal propeptide of type III procollagen (PIIINP) in serum as an indicator of tissue repair was studied in 71 surgical patients undergoing minor, moderate abdominal, major abdominal, or hip surgery. An increase in serum PIIINP concentrations took place within the first week, and its magnitude was related to the extent of the soft-tissue operations. After the hip replacement, the maximum PIIINP concentration was reached somewhat later. Very high levels of serum PIIINP were seen in three patients with serious wound infections. The serum PIIINP antigenicity consisted both before and after surgery of equal proportions of two forms, one corresponding to the propeptide as set free during synthesis of new collagen and the other being larger and probably derived from turnover of type III collagen fibers. The proportion of the latter form was accentuated in infection. In contrast, in the wound the form derived from synthesis of type III collagen predominated. These results suggest that the postoperative increase in serum PIIINP levels is partly the result of tissue repair and partly the result of whole-body turnover of type III collagen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2321135

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  Collagen synthesis in intact skin is suppressed during wound healing.

Authors:  L Ihlberg; K Haukipuro; L Risteli; A Oikarinen; M I Kairaluoma; J Risteli
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

2.  Changes in collagen metabolites in serum after cemented hip and knee arthroplasty.

Authors:  S Joerring; L T Jensen
Journal:  Arch Orthop Trauma Surg       Date:  1993       Impact factor: 3.067

3.  N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone.

Authors:  Shalender Bhasin; E Jiaxiu He; Miwa Kawakubo; E Todd Schroeder; Kevin Yarasheski; Gregory J Opiteck; Alise Reicin; Fabian Chen; Raymond Lam; Jeffrey A Tsou; Carmen Castaneda-Sceppa; Ellen F Binder; Stanley P Azen; Fred R Sattler
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

4.  Types I and III procollagen extension peptides in serum respond to fracture in humans.

Authors:  S Joerring; L T Jensen; G R Andersen; J S Johansen
Journal:  Arch Orthop Trauma Surg       Date:  1992       Impact factor: 3.067

5.  Synthesis of type I collagen in healing wounds in humans.

Authors:  K Haukipuro; J Melkko; L Risteli; M Kairaluoma; J Risteli
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

6.  Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas.

Authors:  T A Wiklund; C P Blomqvist; L Risteli; J Risteli; I Elomaa
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Collagen turnover after tibial fractures.

Authors:  S Joerring; M Krogsgaard; H Wilbek; L T Jensen
Journal:  Arch Orthop Trauma Surg       Date:  1994       Impact factor: 3.067

8.  Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis.

Authors:  Jo Seddon; Victoria Kasprowicz; Naomi F Walker; Ho Ming Yuen; Henry Sunpath; Liku Tezera; Graeme Meintjes; Robert J Wilkinson; William R Bishai; Jon S Friedland; Paul T Elkington
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

9.  Markers of collagen synthesis and degradation are increased in serum in severe sepsis: a longitudinal study of 44 patients.

Authors:  Fiia Gäddnäs; Marjo Koskela; Vesa Koivukangas; Juha Risteli; Aarne Oikarinen; Jouko Laurila; Juha Saarnio; Tero Ala-Kokko
Journal:  Crit Care       Date:  2009-04-09       Impact factor: 9.097

10.  Type III collagen metabolism in soft tissue sarcomas.

Authors:  T A Wiklund; I Elomaa; C P Blomqvist; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.